HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse

This article was originally published in The Pink Sheet

Executive Summary

Ingredient in J&J's Imodium and numerous OTC generics acts on opioid receptors in the gut to slow movement in the intestines and decrease bowel movements, but dosing at much higher than recommended amounts can lead to serious problems including severe heart rhythm problems and death.

You may also be interested in...



Opioid REMS Revisions Reflect Some, Not All, Stakeholder Concerns

US FDA's education blueprint now asks sponsors to extend REMS to health providers beyond prescriber, but pain classifications remain unchanged.

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.

Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price

Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS122607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel